Did Mark Cuban and the Dow Just Prove Goldbugs Right?

Source: JT Long of The Gold Report  (02/12/2016)
Did Mark Cuban and the Dow Just Prove Goldbugs Right?
When celebrity investor Mark Cuban announces to the world that he is investing in gold, is that a sign that the ride up is just getting going, or that it has already peaked? The Gold Report reached out to long-time experts in the sector for a better understanding of what is moving the markets and what that means for junior mining stocks. read more >

With Gold Looking Up, Haywood's Geordie Mark Offers Two Names for Now, Two for Later

Source: Brian Sylvester of The Gold Report  (02/11/2016)
With Gold Looking Up, Haywood's Geordie Mark Offers Two Names for Now, Two for Later
Geordie Mark, head of mining research with Haywood Securities, sees opportunity in both development-stage and producing precious metals equities, especially those domiciled in countries like Canada and Australia, where the currency has depreciated considerably against the U.S. dollar. read more >
Management Q&A: View from the Top

CorMedix Transformative Anti-Infective Technology for Catheters Developed to Decrease Serious Drug-Resistant Infections: CEO Randy Milby

Managment Q&A: View from the Top
Source: George S. Mack of The Life Sciences Report  (02/11/2016)
Patients on dialysis and cancer patients with indwelling catheters live with the possibility of contracting drug-resistant infections that can become more life threatening than their primary diseases. CorMedix Inc., says CEO Randy Milby, is developing a platform that has shown impressive results in preventing serious bloodstream infections. read more >

Healthy Biotech Growth from Four Seedling Stocks: Raghuram Selvaraju of Rodman & Renshaw

Source: George S. Mack of The Life Sciences Report  (02/10/2016)
Healthy Biotech Growth from Four Seedling Stocks: Raghuram Selvaraju of Rodman & Renshaw
Raghuram "Ram" Selvaraju of Rodman & Renshaw has made the micro- and small-cap biotech universe his specialty, and his track record is impressive. In this interview, the former big pharma researcher details four growth names that could follow in the footsteps of previous winners. read more >

Joe Reagor's Equity Picks for Patient Pickers

Source: Brian Sylvester of The Gold Report  (02/08/2016)
Joe Reagor's Equity Picks for Patient Pickers
Picking gold and silver equities in a stagnant price environment is a stock picker's game that requires a particular thesis—and a fair portion of patience, says Joe Reagor, an analyst with ROTH Capital Partners. read more >

Brian Bagnell's Tips for Smart Oil and Gas Investing

Source: Tom Armistead of The Energy Report  (02/04/2016)
Brian Bagnell's Tips for Smart Oil and Gas Investing
In today's tough price environment where most oil and gas juniors are losing money, a strong balance sheet is the key to survival, says Brian Bagnell, a research analyst for Macquarie Capital Markets. He shares his tips on identifying companies that can weather the storm. read more >

Senior Gold Producer Goldcorp Takes Large Stake in Nevada's Gold Standard Ventures

Contributed Opinion
Source: Thibaut Lepouttre of Caesars Report Exclusively for Streetwise Reports   (02/04/2016)
Senior Gold Producer Goldcorp Takes Large Stake in Nevada's Gold Standard Ventures
When Gold Standard Ventures announced on February 1 that Goldcorp would be investing CA$16.1 million for 9.9% of the junior's shares, industry watchers took notice. In this analysis written exclusively for Streetwise Reports, Thibaut Lepouttre, editor of Caesars Report, speculates on why the major acted when and where it did, and what it might mean for the future. read more >
Management Q&A: View from the Top

Advanced Stem Cell Manufacture Saves Lives and Prints Money: Stewart Washer of Cynata Therapeutics

Managment Q&A: View from the Top
Source: Peter Byrne of The Life Sciences Report  (02/03/2016)
Stewart Washer
In this interview, Cynata's executive chairman Stewart Washer tells The Life Sciences Report why his company's technology, in studies for graft-versus-host disease, has proven itself a profit driver. read more >
Expert Investing Ideas

"AKG should deliver free cash flow in 2017."

The Gold Report Interview with Geordie Mark


"The Neutrolin platform positions CRMD particularly well going forward."

The Life Sciences Interview with Ram Selvaraju


"CYP has the only truly sustainable production platform for MSCs."

The Life Sciences Interview with Ram Selvaraju


Look North for Value-Priced Growth in Healthcare: StoneCastle's Bruce Campbell

Source: George S. Mack of The Life Sciences Report  (02/03/2016)
Look North for Value-Priced Growth in Healthcare: StoneCastle's Bruce Campbell
Canada encompasses healthcare-related businesses that are generating cash flow and flourishing. Bruce Campbell of StoneCastle Investment Management has managed both U.S. and Canadian portfolios: He knows both spheres, and as a hedge fund and mutual fund manager he has made a specialty in acquisitions of cash-generating healthcare companies. read more >

U.S. Global's Ralph Aldis on the Life-Changing Magic of an Asset Allocation Plan

Source: JT Long of The Gold Report  (02/01/2016)
U.S. Global's Ralph Aldis on the Life-Changing Magic of an Asset Allocation Plan
You have to have a plan and stick to it, says U.S. Global Investors Fund Manager Ralph Aldis. He shares seven companies he is sticking with come low gold prices or a high Purchasing Managers Index. read more >
Management Q&A: View from the Top

A Small-Cap Biotech with Big Ideas for Acute Infections and Cancers: Cellceutix's Leo Ehrlich and Dr. Daniel Jorgensen

Managment Q&A: View from the Top
Source: George S. Mack of The Life Sciences Report  (01/27/2016)
Leo Ehrlich
Drug development seems to move at a snail's pace, but Cellceutix Corp.'s CEO Leo Ehrlich says his company has jumped through the most time-consuming hoops of development and now has a diversified pipeline with three main drug candidates, any of which could become the lead program with new data in 2016. read more >